Boston to trial new-generation Taxus stent
This article was originally published in Clinica
Executive Summary
The US FDA has given Boston Scientific the green light to test its new paclitaxel-eluting coronary stent system in a pivotal clinical trial. The ATLAS trial will assess Taxus Liberte, the next generation of the firm's current Taxus Express2 stent.